Dr Hernan A Bazan (South Rampart Pharma)2024-07-01T10:00:21
This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines. Its benefits mean it is poised to disrupt the $87 billion pain management market and ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-18T11:12:00Z
2026-11-06T07:26:00Z
Author Dr Tina Rogers
2026-10-30T07:30:00Z
Sponsored by Aptamer Group
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, Drug Target Review
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-04-04T15:03:09
Sponsored by Agilent
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2026-11-06T07:26:00
Author Dr Tina Rogers
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud